| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) |
| 10 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 28 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer ... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. (collectively, “Innovent”), pursuant to w... |
| 25 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
The name of the corporation is Spero Therapeutics, Inc. (the “Corporation”). |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
First and only oral carbapenem antibiotic approved in the US |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025 |
| 30 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 19 Dec 2025 |
8-K: Other Events
On December 19, 2025, Spero Therapeutics, Inc. (the “Company”) announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”), filed a New Drug Application (“NDA”) resubmission to the ... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) |
| 18 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 28 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Spero Therapeutics and GSK Announce PIVOT-PO phase 3 study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025 |
| 28 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
CAMBRIDGE, Mass., April 28, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial inf... |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025 |
| 28 Feb 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
Loading...